Zacks Investment Research Downgrades Sartorius (SARTF) to Sell

Zacks Investment Research lowered shares of Sartorius (OTCMKTS:SARTF) from a hold rating to a sell rating in a research report released on Tuesday.

According to Zacks, “Sartorius AG is a pharmaceutical and laboratory equipment supplier. The company manufactures equipment for biomolecular and microbial separations, cell culture, concentration, fermentation and purification. Sartorius AG is headquartered in Goettingen, Germany. “

Sartorius stock opened at $109.50 on Tuesday. Sartorius has a twelve month low of $109.50 and a twelve month high of $149.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.62 and a quick ratio of 1.00.



Sartorius (OTCMKTS:SARTF) last posted its quarterly earnings data on Tuesday, October 23rd. The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.05. Sartorius had a return on equity of 20.21% and a net margin of 9.09%. The company had revenue of $459.56 million during the quarter, compared to analysts’ expectations of $460.00 million. Research analysts forecast that Sartorius will post 2.95 EPS for the current fiscal year.

Sartorius Company Profile

There is no company description available for Sartorius AG.

Recommended Story: Preferred Stock

Get a free copy of the Zacks research report on Sartorius (SARTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply